Premium
Genetically engineered T cells for the treatment of cancer
Author(s) -
Essand M.,
Loskog A. S. I.
Publication year - 2013
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/joim.12020
Subject(s) - chimeric antigen receptor , genetically engineered , genetically modified organism , immunotherapy , medicine , antigen , cancer immunotherapy , cancer , immunology , adoptive cell transfer , cancer research , cancer cell , ex vivo , t cell , in vivo , biology , immune system , gene , microbiology and biotechnology , genetics
T‐cell immunotherapy is a promising approach to treat disseminated cancer. However, it has been limited by the ability to isolate and expand T cells restricted to tumour‐associated antigens. Using ex vivo gene transfer, T cells from patients can be genetically engineered to express a novel T cell receptor or chimeric antigen receptor to specifically recognize a tumour‐associated antigen and thereby selectively kill tumour cells. Indeed, genetically engineered T cells have recently been successfully used for cancer treatment in a small number of patients. Here we review the recent progress in the field, and summarize the challenges that lie ahead and the strategies being used to overcome them.